EXTX — Exact Therapeutics AS Cashflow Statement
0.000.00%
Last trade - 00:00- NOK237.40m
- NOK192.16m
Annual cashflow statement for Exact Therapeutics AS, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -14.8 | -33.1 | -58.6 | -40.1 | -48.3 |
| Depreciation | |||||
| Non-Cash Items | -0.318 | 7.34 | 2.53 | -0.607 | 3.96 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.28 | -1.15 | -0.88 | 4.92 | -2.01 |
| Change in Accounts Receivable | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -12.5 | -26 | -55.1 | -33.9 | -44.3 |
| Capital Expenditures | -1.4 | -3.96 | -1.63 | -0.251 | -3.09 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -21.6 | 2.98 | 0.616 | 20.9 | 0.945 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -23 | -0.981 | -1.01 | 20.6 | -2.15 |
| Financing Cash Flow Items | -0.01 | -3.8 | -0.117 | -0.12 | -1.25 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.114 | 143 | -0.047 | -0.531 | 23.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -35.5 | 115 | -56.3 | -13.5 | -23 |